Stocks and Investing
Stocks and Investing
Tue, September 20, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, September 19, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Robert Burns Maintained (ADCT) at Strong Buy with Increased Target to $21 on, Sep 19th, 2022
Robert Burns of HC Wainwright & Co., Maintained "ADC Therapeutics SA" (ADCT) at Strong Buy with Increased Target from $20 to $21 on, Sep 19th, 2022.
Robert has made no other calls on ADCT in the last 4 months.
There are 2 other peers that have a rating on ADCT. Out of the 2 peers that are also analyzing ADCT, 1 agrees with Robert's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Matthew Harrison of "Morgan Stanley" Downgraded from Buy to Hold and Decreased Target to $11 on, Friday, September 9th, 2022
This is the rating of the analyst that currently disagrees with Robert
- Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $29 on, Wednesday, August 10th, 2022
Contributing Sources